Medicare Part B PD-1/PD-L1 Step Therapy for Basal Cell Carcinoma and Squamous Cell Carcinoma
Customize your policy alerts
Sign up for zing_health Policy 6304-D alerts
Get alerted when Policy 6304-D changes without checking for updates manually.
Monitor payer policy activity
This policy governs Medicare Part B coverage of specified PD-1/PD-L1 products for members receiving treatment for basal cell carcinoma or squamous cell carcinoma. Libtayo is preferred, while coverage of non-preferred Keytruda requires an applicable clinical exception through prior authorization.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.